Table 4.

Consequences of REV7 depletion in cancer studies.

Organ	Cancer Type	REV7 Depletion	Reference
Bladder	Bladder	Inhibits cancer cell proliferation and viability	(173)
Breast	Triple negative	Inhibits breast cancer cell migration, invasion, and EMT	(174)
Cervical	Cervical	Enhances sensitivity to cisplatin	(166)
Esophagus	Esophageal squamous cell	Increases radiosensitivity; decreases tumor burden in mice	(175)
Brain	Glioma	Inhibits cell proliferation; increases sensitivity to cisplatin	(170)
		Increases ionizing radiation-induced cytotoxicity; increases rate of damage due to ionizing radiation	(168)
		Increases radiosensitivity; inhibits CD8+ cell death	(169)
Lung	Small cell	Suppresses cell proliferation; activates apoptotic pathway	(172)
	Non-small cell	Increases sensitivity to cisplatin and doxorubicin	(252)
		Promotes cisplatin sensitivity; increases cisplatin-induced senescence	(171)
		Inhibits cell migration, invasion and EMT; decreases distant metastasis	(211)
Pharynx	Nasopharyngeal	Increases sensitivity to cisplatin and irradiation; decreases rate of mutagenesis	(167)
Ovary	Ovarian clear cell carcinoma	Decreases cell proliferation; increases sensitivity to cisplatin	(181)
Pancreas	Pancreatic ductal adenocarcinoma	Reduces proliferation; increases sensitivity to cisplatin	(160)
Skin	Melanoma	Reduces melanoma cell proliferation, migration, and invasion	(159)
Testicle	Testicular germ cell	Increases sensitivity to cisplatin and doxorubicin; overcomes chemoresistance; decreases cell proliferation	(161, 162)